Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07054190 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07054190 is a Phase 2 study that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 60 participants.
The verdict
NCT07054190, a Phase 2 study, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Interventions
- DRUG Letrozole
- DRUG Ribociclib
- DRUG Inavolisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2027-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07054190
The ClinicalTrials.gov registry entry for NCT07054190 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Letrozole is the first listed.
NCT07054190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07054190 about?
NCT07054190 is a clinical study titled "A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer". This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
What is the current status of trial NCT07054190?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-09-09. Estimated completion is 2027-09-28.
What interventions are being tested in trial NCT07054190?
The interventions under investigation include: Letrozole (DRUG), Ribociclib (DRUG), Inavolisib (DRUG).
Who is sponsoring clinical trial NCT07054190?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.